Clinical Trials · NCT04076059
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Astellas Pharma China, Inc.
- Enrollment
- 180
- Start date
- Sep 2019
- Locations
- 28 sites, China
- Primary endpoint
- Time to Prostrate Specific Antigen (PSA) Progression